You are here
Samsung Biologics aims to raise 2.25t won in IPO
SAMSUNG Biologics Co is seeking to raise as much as 2.25 trillion won (S$2.77 billion) from a South Korean initial public offering, taking an important step towards its goal of becoming the world's largest contract manufacturer of biological medicines.
The drug-making arm of
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org